Tag: Bayer

Bayer AG is a German multinational chemical, pharmaceutical and life sciences company. It is headquartered in Leverkusen, where its illuminated sign is a landmark. Bayer’s primary areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals and biotechnology products; and high value polymers.

Bayer will develop new cardiovascular therapies with the Broad Institute

Bayer and the Broad Institute announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases.

Nativa won in court its patent dispute with Bayer

The Arbitration Court of Moscow region decided to reject the claim of Bayer (Bayer Healthcare LLC) to Nativa, a Russian company, aimed at recognizing and stopping the actions that violate the exclusive rights of the plaintiff.

Bayer plans to increase the share of its localized products in Russia

Bayer intends to raise the share of its localized products in Russia to 30% of the total sales. The company is already implementing a number of large-scale projects to localize the manufacturing of innovative medicines

Top pharma players place their stakes on Chinese market

china street
Pharmaceutical giant Bayer reported a robust growth in its pharmaceutical business in China, as its total sales stood at 17 billion yuan ($2.67 billion) in 2017, a year-on-year growth of 18.3 percent.

Bayer, Novartis and Teva topped February sales rankings in Russia

According to DSM Group, in February 2018, the commercial market of medicinal products amounted to 80.6 billion rubles (in retail prices). Compared to January 2018, the market volume increased by 4.0%.

Bayer received a warning letter from FDA

The German drugmaker, which is taking over U.S. seed maker Monsanto, is addressing the FDA’s complaints regarding manufacturing practices, which stem from a routine inspection in January.

Bayer aims to intensify its strategic pharmaceutical research

Bayer announced to further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership

Bayer and PeptiDream started a drug discovery collaboration

Bayer and PeptiDream have entered into a global drug discovery collaboration across multiple therapeutic areas and target classes

Loxo Oncology and Bayer sealed a drug development deal

cancer lab diagnostic
Loxo Oncology, Inc. announced that it has entered into a global collaboration with Bayer

Bayer and Compugen established a process development and service agreement

Compugen Ltd., has advanced COM902, its lead anti-TIGIT antibody, into manufacturing for an investigational new drug application anticipated in 2019

Primer Capital and Bayer become partners to support biotech startups

Primer Capital, a venture capital biotech fund, and Bayer have signed an agreement on the joint work to identify and develop the promising startups

Bayer and Ginkgo Bioworks will create new biotech company

Bayer and Ginkgo Bioworks will create a new company focused on the plant microbiome

Bayer will develop kidney diseases treatment along with Vanderbilt University

Vanderbilt University Medical Center and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases

Bayer recieved EU marketing authorization for Stivarga

Bayer announced the European Commission (EC) has granted marketing authorization for Stivarga® (regorafenib)

Bayer obtained FDA priority review for cancer drug

German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

Bayer got FDA approval for liver cancer drug

Bayer announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been pr...